Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00321_DB00472_nanopub.RAWtsZkxB4IHkU4lfkScv34AfAR3pHCb-nwrg-ppdVF6o#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00321_DB00472 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00321_DB00472 label "DDI between Amitriptyline and Fluoxetine - The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluoxetine is initiated, discontinued or dose changed. [drugbank_resource:DB00321_DB00472]" assertion.
- drugbank_resource:DB00321_DB00472 identifier "drugbank_resource:DB00321_DB00472" assertion.
- drugbank_resource:DB00321_DB00472 title "DDI between Amitriptyline and Fluoxetine - The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluoxetine is initiated, discontinued or dose changed." assertion.
- drugbank:DB00321 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00321_DB00472 assertion.
- drugbank:DB00472 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00321_DB00472 assertion.